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Abstract
Thomsen-Friedenreich antigen (TF-Ag) is expressed in
many carcinomas, including those of the breast, colon,
bladder, and prostate. TF-Ag is important in adhesion
and metastasis and as a potential immunotherapy
target. We hypothesized that passive transfer of JAA-
F11, an anti–TF-Ag monoclonal antibody, may create a
survival advantage for patients with TF-Ag–expressing
tumors by cytotoxicity, blocking of tumor cell adhesion,
and inhibition of metastasis. This was tested using
in vitro models of tumor cell growth; cytotoxicity
assays; in vitro, ex vivo, and in vivo models of cancer
metastasis; and, finally, in vivo effects in mice with
metastatic breast cancer. Unlike some anti–TF-Ag anti-
bodies, JAA-F11 did not enhance breast carcinoma cell
growth. JAA-F11 did not induce the killing of 4T1 tumor
cells through complement-dependent cytotoxicity or
apoptotic mechanisms. However, JAA-F11 blocked the
stages of metastasis that involve the adhesion of
human breast carcinoma cells to human endothelial
cells (human umbilical vein endothelial cells and
human bone marrow endothelial cells 60) in in vitro
static adhesion models, in a perfused ex vivo model,
and in murine lung vasculature in an in vivo metastatic
deposit formation assay. JAA-F11 significantly ex-
tended the median survival time of animals bearing
metastatic 4T1 breast tumors and caused a > 50% in-
hibition of lung metastasis.
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Introduction
During carcinogenesis, alterations in the biosynthesis of
carbohydrate structures occur, and several different carbo-
hydrate moieties linked to either proteins or lipids have been
recognized as tumor-associated glycoantigens.One of them
is the Thomsen-Friedenreich antigen (TF-Ag), which was dis-
covered by Thomsen, Friedenreich, and Hueber in the late
1920s [1]. TF-Ag is a disaccharide galactoseb1–3N-acetyl
galactosamine attached to proteins by an a O-serine or O-
threonine linkage. It is cryptic on cell membranes of various
normal cells, including epithelial cells, red blood cells, and
lymphocytes [2], because it is either further glycosylated or
covalently masked by highly charged sialic acid [3]. TF-Ag is
exposed and immunoreactive, however, to an array of adeno-
carcinomas, including breast, lung, bladder, prostate, and pan-
creas adenocarcinomas [1,2,4,5]. The expression of TF-Ag has
been proposed as a tool for the detection of tumors and as a
criterion for prognosis [6]. TF-Ag densities predict the histo-
pathological grade of carcinomas [7], their invasive potential,
and the probability of early recurrence in breast [1,8,9], urinary
bladder, and prostatic tumors [10].
TF-Ag is not simply an immunopathological marker. It has
been postulated to have a role in adhesion and metastasis [1].
Reversible or irreversible intercellular adhesion is one of
the primary steps in metastasis [11], which may occur when
TF-Ag recognizes ligands such as galectins or other lectins
[5,12]. There is an increased expression of TF-Ag in meta-
static tumors, and lectins that bind TF-Ag are in some of the
common sites of metastatic tumor growth [13]. Ligands for
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TF-Ag adhesion have been found in the vascular endothe-
lium, liver, bone marrow, and lymph nodes [14,15], and this
may explain how TF-Ag levels are related to carcinoma ag-
gressiveness [16]. Additional evidence that TF-Ag is involved
in tumor metastasis is that adhesion of breast tumor cells to
normal breast cells was blocked by polyclonal antibody to
TF-Ag [11]. Thus, TF-Ag was chosen for this study as a
cancer-associated antigen proposed to be involved in tumor
progression and metastasis [3,6,17–21], which could be
clinically significant in tumor immunotherapy.
There have been several reports concerning the immuno-
therapeutic value of an induced immune response to
carbohydrate tumor-associated antigens [19,22–26]. In a
particularly relevant work by Springer et al. [11], vaccination
with TF-Ag–Tn vaccine composed of O MN red blood cell–
derived glycoprotein resulted in improved breast cancer
patient survival, even though only small amounts of IgM
antibody were produced. Interestingly, immunization of
breast cancer patients with Globo H (a TF-Ag–containing
hexasaccharide) conjugated to keyhole limpet hemocyanin
and injected with the adjuvant QS21 also resulted in most
patients forming only an IgM response [27]. Although IgM
(representing a lessmature immune response) is generally of
lower affinity and specificity than IgG, many of the studies
concerning antibodies to TF-Ag involve IgM responses.
In contrast, by immunization with a bovine serum albumin
(BSA) conjugate of Galb1–3GalNAc, we were able to gen-
erate a hybridoma designated as JAA-F11, which produces
IgG3 monoclonal antibody (mAb) against TF-Ag [28]. IgG
subclasses are usually superior to those of IgM in terms of
higher affinity, specificity, and lower background binding.
JAA-F11 characterization using the structurally relevant sac-
charide GM1 confirmed the ability of JAA-F11 antibody to
discriminate between a and b linkages to Gal and to prefer
Galb1–3GalNAca to GM1 [28]. This is important because it
shows that related carbohydrate structures on normal cells
would not bind the JAA-F11 antibody. This point also dif-
ferentiates JAA-F11 from the anti–TF-Ag antibody 170H82,
which was reported previously by Dessureault et al. [29]. The
170H82 antibody recognizes both Galb1–3GalNAca and
Galb1–3GalNAcb derivatives and, therefore, could poten-
tially interact with carbohydrate structures expressed in
normal tissues such as GM1, whereas JAA-F11 does not.
Furthermore, the lack of JAA-F11 binding to NANAa2–
3Galb1–3GalNAca-O-DP-BSA, the sialylated analog of TF-
Ag derivatives commonly found in normal cells [28], also
suggests that JAA-F11 may recognize tumor tissues with
higher specificity in either localization or therapy. In a pre-
vious study of six human breast adenocarcinoma tissues, all
stained positively for JAA-F11. One sample each of the brain,
ovary, lung, kidney, colon, liver, testes, endometrium, heart,
and spleen was tested and found to be negative [28]. Some
antibodies and lectins that bind to TF-Ag have been found to
increase tumor cell growth in vitro [12,30–32], but, impor-
tantly, our data show that JAA-F11 does not enhance growth.
Based on the above points, we hypothesize that passive
transfer of JAA-F11 anti–TF-Ag IgG3 antibody could create a
survival advantage for patients with TF-Ag–expressing
tumors either by blockade of tumor cell adhesion to the
vascular endothelium or by different mechanisms of cellular
cytotoxicity. This was tested in in vitro models of cellular
cytotoxicity [complement-dependent cytotoxicity (CDC) and
apoptosis]; in an in vitromodel of the direct effect of JAA-F11
on tumor cell growth; in in vitro, ex vivo, and in vivo human
models of metastasis involving the adhesion of human
breast cancer cells to the vascular endothelium [5,33]; and,
finally, in in vivo effects in mice with metastatic breast
cancer. In our experiments, JAA-F11 did not induce the
significant killing of 4T1 tumor cells in vitro through CDC or
apoptotic mechanisms. However, the addition of the antibody
to in vitro cultures of tumor cells inhibited their growth by a
modest (up to 16%) but significant extent (P < .01). In in vitro
and ex vivo models of human breast cancer metastasis,
JAA-F11 inhibited tumor cell adhesive interactions with
human umbilical vein endothelial cells (HUVEC) and human
bone marrow endothelial cells (HBMEC), as well as with
well-differentiated porcine microvessels. These in vitro
effects translated in vivo into a significant (P = .05) extension
of the survival time of animals bearing 4T1 breast cancer
tumors and > 50% inhibition of spontaneous lung metas-
tasis (P = .0155).
Materials and Methods
Antibody Purification
JAA-F11 mAb was partially purified from a supernatant
using ammonium sulfate precipitation followed by dialysis
and lyophilization. A stock solution of partially purified anti-
body was made at 1 mg/ml total protein containingf160 mg/
ml JAA-F11 and used for in vitro experiments. For in vivo
experiments, the antibody was additionally purified and con-
centrated using size exclusion chromatography on a Sepha-
dex G-200 column (Pharmacia Fine Chemicals, Piscataway,
NJ) yielding a stock solution containingf1.2 mg/ml purified
JAA-F11 antibody.
Cell Lines and Cultures
Themousemammary gland adenocarcinoma cell line 4T1
was purchased from ATCC (Manassas, VA; no. CRL-2539).
The 4T1 cell line is a relevant animal model for stage IV
human breast cancer [34,35]. When injected into BALB/c
mice, 4T1 produces highly metastatic tumors that can spon-
taneously metastasize to the lung, liver, lymph nodes, and
brain, whereas the primary tumor grows in situ [34–36].
Mouse myeloma P3-X63-Ag8 (ATCC; no. CRL-1580), which
served as the fusion partner for producing JAA-F11 hybrid-
oma [28], was used in this study as a TF-Ag control cell line.
The highlymetastaticMDA-MB-435 human breast carcinoma
cell line was kindly provided by Dr. J. Price (M. D. Anderson
Cancer Center, Houston, TX). The tumor cell line was grown
in RPMI 1640 medium supplemented with 10% fetal bovine
serum (FBS) and adjusted to contain 2 mM L-glutamine,
1.5 g/l sodium bicarbonate, 4.5 g/l glucose, 10 mM HEPES,
and 1.0 mM sodium pyruvate. HUVEC were purchased
from Cascade Biologics (Portland, OR). Basal Medium 200
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(Cascade Biologics) supplemented with low-serum growth
supplement containing FBS (final concentration, 2% vol/vol),
hydrocortisone, human fibroblast growth factor, heparin, and
human epidermal growth factor was used for culturing
HUVEC. The cells at population doublings of approximately
8 to 12 were used for adhesion experiments. HBMEC-60
were kindly provided by Dr. C. E. van der Schoot (University
of Amsterdam, Amsterdam, The Netherlands). HBMEC-60
were shown tomaintain their normal phenotype and adhesive
properties, specifically their ability to bind hematopoietic
progenitor cells [37]. Basal Medium 200 (Cascade Biologics)
supplemented with 20% FBS and low-serum growth supple-
ment containing hydrocortisone, human fibroblast growth
factor, heparin, and human epidermal growth factor was used
for HBMEC-60. All cells were maintained as monolayer
cultures in a humidified incubator in 5%CO2/95% air at 37jC.
Immunohistochemistry
The vector Mouse on Mouse (MOM) Immunodetection Kit
(Vector Laboratories, Burlingame, CA) was used to detect the
expression of TF-Ag on paraffin-embedded formalin-fixed
tissue samples with JAA-F11 antibody. After blocking endog-
enous peroxidase with 3% H2O2 and endogenous Ig using a
mouse Ig block reagent, a stock solution of purified JAA-F11
antibody (1.2 mg/ml) diluted 1:5 (vol/vol) with the MOM
diluent was applied for 1 hour as primary antibody. Bio-
tinylated MOM anti-mouse IgG reagent, ABC reagent, and
3c3-diaminobenzidine HCl were used for subsequent color
development. Next, slides were counterstained with hema-
toxylin and examined by light microscopy.
Indirect Cellular Enzyme-Linked Immunosorbent
Assay (ELISA)
Two-hundred-microliter aliquots of a single-cell suspen-
sion (2  105 cells) of 4T1, MDA-MB-435, or P3-X63-Ag8
myeloma cells that had been harvested by scraping without
trypsin were placed in tubes, and 200 ml of 4% formaldehyde
solution in phosphate-buffered saline (PBS) was added for
20 minutes to fix the cells. The tubes were centrifuged and
decanted, and 200 ml of PBS–Tween–1%BSAwas added to
each to prevent fixed cells from drying. The tubes with fixed
cells were stored at 4jC overnight for up to 2 weeks. For
peroxidase-linked immunoassay, 200 ml of indicated JAA-
F11 mAb dilutions was added to each tube and incubated
for 2 hours at 37jC. The tubes were washed thrice with
PBS–Tween (no azide) then centrifuged for 10 minutes at
1200 rpm between each wash. Two hundred microliters of
anti-mouse IgG (g-chain–specific) peroxidase conjugate
(1:1000, 0.7 mg/ml; Sigma, St. Louis, MO) in PBS–
Tween–1% BSA was added to the tubes for 1 hour at room
temperature (RT). After three washes, O-phenylenediamine
dihydrochloride substrate (Sigma) was used for color de-
velopment, which was terminated after 1 hour with 100 ml of
stop solution (1 N H2SO4). The tubes were centrifuged at
1200 rpm for 10 minutes, and 200 ml of the supernatant
was removed to microtiter plate wells. The plate was read
at 490 nm using a well of unreacted substrate as blank.
Inhibition was performed by adding 0.4 mg of TF-Ag–BSA
conjugate to the 1:5 dilution of F11, incubating for 1 hour at
RT, and centrifuging in a microfuge for 3 minutes before 4T1
and MDA-MB-435 reactions. Inhibition was calculated as:
1(optical density [OD] inhibited/OD uninhibited).
Effects of JAA-F11 on Tumor Cell Growth In Vitro
To determine the direct effect of JAA-F11 on tumor cell
growth, in vitro 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl-
tetrazoliumbromide (thiazoyl blue,MTT)proliferationanalyses
were performed [38,39]. 4T1 mouse mammary adenocarci-
noma cells (at 2.5 104 cells/well) and MDA-MB-435 human
breast tumor cells (at 1.25  104 cells/well) were plated
in 96-well plates in the presence of JAA-F11 at an indi-
cated concentration or in the presence of a control isotype-
matching antibody at an equivalent concentration. When
plated at these amounts, the cells are in the linear portion of
their growth curves at 72 hours. Cells grown in a culture
medium without antibody and a culture medium alone were
used as additional negative controls. After 68 hours of cell
growth, 10 ml of the tetrazolium salt MTT [38,39] was added
to each well, and the plates were returned to the incubator
for a total growth time of 72 hours. The resulting formazan
product in each well was solubilized by adding 120 ml of 5%
formic acid in isopropanol with forceful mixing, and the
absorbance of each well was measured at 570 nm.
Apoptosis Assay on JAA-F11–Treated Tumor Cells
The APO-BRDU Apoptosis kit (catalog no. AU1001;
Phoenix Flow Systems, San Diego CA) was used with few
changes, as listed below. The kit is based on terminal
deoxynucleotide transferase dUTP nick end labeling assay
(TUNEL) assay technique for labeling DNA breaks and total
cellular DNA to detect apoptotic cells by flow cytometry.
Fixation was performed as suggested in the kit’s directions,
and cells (4T1 andmyeloma, untreated or treatedwith 8 mg/ml
JAA-F11) were incubated for 30 minutes with 1% parafor-
maldehyde before centrifugation, washing, and dropwise
addition of ice-cold ethanol during vortexing. Cells were
stored overnight at 20jC before staining. Staining was
performed as stated in the kit’s directions, with the exception
that the supernatant was not aspirated off but rather poured
off, and the tube was blotted and vortexed. After DNA label-
ing and staining with fluorescein and propidium iodide, the
cells were analyzed on a FACS Calibur machine (Becton
DickinsonBiosciences, Franklin Lakes,NJ). Appropriate con-
trols were included in the kit and prepared as stated above.
CDC
The CytoTox 96 Nonradioactive Cytotoxicity Assay (Pro-
mega, Madison, WI) based on the release of lactate dehy-
drogenase (LDH) was performed in this study to analyze the
effect of JAA-F11antibody on4T1cells inCDCassays in vitro.
As a colorimetric alternative to 51Cr release cytotoxicity
assays, this assay quantitatively measures LDH, a stable
cytosolic enzyme that is released on cell lysis, in much the
sameway as 51Cr is released in radioactive assays. A mouse
anti-mouse H-2Dd mAb (Becton Dickinson), which recog-
nizes an epitope on N-terminal domains (a1 and a2 of
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H-2Dd) [38,40,41], was used as positive control. JAA-F11 and
anti–H-2Dd mAb were both brought to 0.01 mg/ml. The
source of the complement was baby rabbit serum, which
was reconstituted as directed (CL3441, 10 1-ml lyophilized
vials; Cedarlane Laboratories, Burlington, NC). The comple-
ment was used within 1 hour of reconstitution. The optimal
cell concentration for the assay was determined as 1  104
cells/50 ml per well.
Fifty microliters of 4T1 cell suspension (or medium), 40 ml
of complement dilutions (or medium), and 10 ml of antibody
solutions (or PBS) were mixed in each well in quadruplicate
sets in a round-bottom 96-well culture plate by centrifuging at
1000 rpm for 4 minutes. The plate was incubated for 2 hours
at 37jC with 5% CO2. Forty-five minutes before harvesting
the supernatant, 10 ml of lysis solution (10) for each 100 ml of
target cells was added to the wells containing the target cell
maximum LDH release control and the volume correction
control. After 2 hours of incubation, the plate was centrifuged
at 1000 rpm for 4minutes, and 50-ml aliquots were transferred
from all wells to a fresh 96-well plate. Next, 50 ml of recon-
stituted substrate mix was added to each well, then the plate
was covered with foil to protect from light and was incubated
for 30 minutes at RT. The reaction was stopped by adding
50 ml of stop solution to each well, and absorbance was re-
corded using a microplate reader at 490 nm.
Static Adhesion Assay
Static adhesion experiments were performed exactly as
described [5,17]. A single-cell suspension of cancer cells
prelabeled with a 3-mg/ml solution of acridine orange (5 
104 cells/chamber in 2.5 ml of a culture supernatant at
approximately 50 mg/ml antibody) was added to the mono-
layer of endothelial cells grown to confluence directly on
microscope slides using four-well chamber slides (Nalge-
Nunc, Naperville, IL). The chambers were sealed, and cells
were allowed to adhere for 1 hour at 37jC, after which the
chambers were inverted and left upside down for 30 min-
utes to allow for sedimentation of nonadherent cells. Next, the
medium was drained, and samples were gently rinsed with
PBS, fixed for 30 minutes in 2% formaldehyde solution in
PBS,mountedwith cover glass, and examined by fluorescent
microscopy. Four random fields in each well were photo-
graphed at 250 magnification, and the total number of
adhered cells in every field was counted. The assay was
performed in quadruplicate for each experimental condition.
Ex Vivo–Perfused Porcine Dura Mater Model
Porcine duramater was used in adhesion experiments, as
described elsewhere [33,42]. Briefly, the dura mater cor-
responding to one hemisphere, collected frommature female
Yucatan miniature swine (Charles River Laboratories, Wil-
mington, MA) within 30 minutes of animal sacrifice (in accor-
dance with the animal care protocol approved by the
University of Missouri), was dissected and flattened onto a
Sylgard-coated 100-mm dish. A major branch of the median
meningeal artery was cannulated, and the dura vasculature
was perfused at 15 ml/min initially with Krebs physiological salt
supplemented with 1.0 mg/ml porcine serum albumin for
20 minutes, then with vessel-labeling solution (0.3 mg/ml ac-
ridine orange in RPMI 1640 supplemented with 10 % FBS
and 1.0 mg/ml porcine albumin) for an additional 40 minutes.
Before injection, cancer cells were prelabeled for 5 minutes
with 3 mg/ml acridine orange solution in RPMI 1640 medium,
rinsed thrice, dissociated from plastic, pipetted to produce
a single-cell suspension, filtered through a 20-mmnylonmesh
to remove cell clumps, and adjusted to 5  104 cells/ml. The
interactions of cancer cells with the dura microvasculature
were monitored and videorecorded at 30 frames/sec using a
fluorescence videomicroscopy system based on a Laborlux
8 microscope (Leitz Wetzlar, Wetzlar, Germany) equipped
with a 75-W xenon lamp and a high-sensitivity charge-
coupled device (CCD) camera (COHU, San Diego, CA).
For subsequent frame-by-frame analysis, the recorded ana-
log videoimages were digitized using a media converter
DVMC-DA2 (Sony, Tokyo, Japan) and Adobe Premier 6 soft-
ware (Adobe Systems, San Jose, CA). JAA-F11 was added
as a culture supernatant, which contained approximately
50 mg/ml antibody.
In Vivo Metastatic Deposit Formation Assay
In vivometastatic deposit formation assay was performed
exactly as previously described [43]. Briefly, 6-week-old
female HsdIcr:Ha(ICR)-scid mice (Harlan, Indianapolis, IN)
were used in this study in accordance with the animal care
protocol approved by the University of Missouri. Before
intravenous injection, MDA-MB-435 human breast carci-
noma cells were prelabeled for 5 minutes with a 3-mg/ml
solution of acridine orange in RPMI 1640 medium, rinsed
thrice with serum-free RPMI 1640 medium, and dissociated
from plastic with a nonenzymatic cell dissociation reagent
(Sigma). Immediately following dissociation, tumor cells were
resuspended using one of the following: 1) complete RPMI
1640 medium (control); 2) undiluted conditioned supernatant
containing JAA-F11 anti–TF-Ag antibody (approximately
50 mg/ml mAb); or 3) undiluted conditioned supernatant con-
taining control antibody; and pipetted to produce a single-cell
suspension. All subsequent manipulations with cancer cells
were performed using the same media composition. To
remove any remaining cell clumps, the tumor cell suspension
was filtered through a 20-mm nylon mesh and adjusted to
contain 5  106 cells/ml. Next, 200 ml (1  106 cells) of a
single-cell suspension of fluorescently labeled MDA-MB-435
cells was injected into the lateral tail vein of experimental
animals. Three hours postinjection, the animals were eu-
thanized, and the lungs were removed, examined by epi-
fluorescence microscopy, and photographed using a QICAM
high-performance digital CCD camera (Quantitative Imaging
Corporation, Burnaby, Canada). At least two identical experi-
ments were performed for each experimental setup. In each
animal, subpleural metastatic deposits were scored in four
random observation fields. The results were calculated and
presented as mean ± SD.
In Vivo 4T1 Mouse Breast Carcinoma Model
To study the effect of JAA-F11 on the in vivo growth of
primary tumors, 4T1 tumors were induced in 20 eight-week-
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old female BALB/c mice by injecting 100 ml of a single-cell
suspension (1  105 viable cells/ml) subcutaneously into the
fat pad area of the right abdominal mammary gland. This
dose (1104 viable tumor cells/mouse) ensures 100% tumor
incidence [34–36]. Three days after the implantation of 4T1
tumor cells, the mice were divided randomly into two groups
and received intraperitoneal administration of either purified
JAA-F11 (120 mg/100 ml per mouse) as treatment or PBS as
control, twice weekly, throughout the duration of the ex-
periment. Beginning on day 11 after implantation, tumor size
wasmeasured every 2 days as follows: twomeasurements of
the tumor, perpendicular to each other and spanning the
largest portion of the tumor in each direction, were performed
with Vernier calipers, and tumor volume was calculated
based on these measurements.
To study the effect of JAA-F11 on the spontaneousmetas-
tasis of 4T1, tumors were induced as above in 40 eight-week-
old female BALB/c mice. Three days after implantation, mice
were randomized into two groups (20 mice/group). One
group received intraperitoneal injections of purified JAA-F11
(120 mg/100 ml per mouse) as treatment, whereas another
group received 100 ml of PBS as control, twice weekly,
throughout the duration of the experiment. To further model
the clinical situation, 2 weeks after tumor implantation, when
spontaneous metastases were present in at least 88% of
control animals, the primary tumors were surgically removed,
leaving only metastatic disease to be studied in the animal
model; this is comparable to a clinical situation where pri-
mary breast tumor is surgically removed and metastatic foci
remain intact [34–36].
Measurement of Tumor Outcome
Mouse weights were measured and weight loss rates
between treated mice and control mice were compared.
Clinical symptoms, such as lack of grooming, rough coat,
rapid and labored breathing, and loss of mobility, were
monitored, recorded, and used as indicators of morbidity.
Mice were sacrificed when weight loss reached 20% or when
moribund. Daily observations were made by both investiga-
tors and animal caretakers. The survival time was recorded
and analyzed by the Kaplan-Meier survival curve (MedCalc,
Mariakerke, Belgium). Organs of interest (primary tumor,
lung, liver, spleen, lymph node, and brain) were collected
and fixed using Z-fixative, and paraffin sections for immuno-
histochemical staining were prepared.
Statistical Analysis
Statistical significance was calculated using t-test, and
error bars represent ± 1 SD of the mean for some experi-
ments and ± 1 SEM for some experiments, as noted in figure
legends. Grubb’s test for outlying observations was used to
determine any outliers for rejection from the data set. Chi-
square analysis was used to determine the statistical sig-
nificance of lung metastases, whereas the Kaplan-Meier
survival curve was used to determine the survival difference
between JAA-F11–treated mice and control mice.
Results
Detection of TF-Ag on Tumor Cells Using JAA-F11 Antibody
The ability of JAA-F11mAb to recognize TF-Ag expressed
in tumor cells in vivo and in vitro was confirmed by immuno-
histochemical analysis of primary 4T1 tumors induced in
BALB/c mice and by indirect cellular ELISA, respectively.
Because JAA-F11 is a mouse mAb and 4T1 is a murine
mammary adenocarcinoma, we used the MOM Immuno-
detection Kit (Vector Laboratories) to detect the expression
of TF-Ag with JAA-F11 on paraffin-embedded formalin-fixed
tissue samples of primary 4T1 tumors removed from BALB/c
mice (Figure 1A and B). The characteristic brown stain
(Figure 1A) is indicative of the JAA-F11 recognition of TF-Ag
Figure 1. (A) Immunohistochemical staining of primary 4T1 breast tumor dissected from BALB/c mice using JAA-F11 as primary antibody. Brown color indicates
the binding of JAA-F11 antibody to the TF-Ag expressed in tumor cells. (B) Nonimmune (no primary antibody) negative control. (C) Whole-cell indirect ELISA
showing 4T1 and MDA-MB-435 dose-dependent reactivity with three JAA-F11 dilutions of 8, 16, and 32 g/ml. TF-Ag P3-X63-Ag8 mouse myeloma cells show no
significant reactivity with JAA-F11. P < .01, comparing 4T1 to myeloma cells and MDA-MB-435 to myeloma cells at all dilutions, using t-test for significance.
Representative of four experiments. Error bars represent ± 1 SEM. (D) Whole-cell indirect ELISA showing the inhibition of JAA-F11 binding to 4T1 and MDA-MB-
435 cells by 0.4 mg of TF-Ag–BSA conjugate. Significant inhibition of JAA-F11 at a 1:5 dilution compared to uninhibited JAA-F11 was seen in both cell types. Error
bars represent ± 1 SEM and *P < .05.
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expressed in cancer cells. No staining was observed in
nonimmune control samples (Figure 1B). In other experi-
ments, radiolocalization of 124I-labeled JAA-F11 showed a
lack of reactivity of other mouse tissues and the localization
of the antibody to 4T1 cells in mice (data not shown).
To test the ability of JAA-F11 to detect the TF-Ag
expressed on surfaces of tumor cells grown in vitro, indirect
cellular ELISA was performed. Mouse myeloma P3-X63-Ag8
cells, which do not express TF-Ag, were used as negative
control in these experiments. Two series of ELISA experi-
ments were performed. In the first series, the binding of
various concentrations of JAA-F11 mAb to the same amount
of cells was measured. The results of these experiments
demonstrated that the binding of JAA-F11 to TF-Ag–
expressing human breast tumor MDA-MB-435 and 4T1
tumor cells was linear and increased in agreement with
escalating mAb concentrations (Figure 1C). In the second
series of ELISA experiments, ELISAwas performed in micro-
titer plates, and various amounts of tumor cells were exposed
to the fixed concentration of the JAA-F11 antibody. This
reaction was also linear with cell number (data not shown).
As expected, JAA-F11 did not react with TF-Agmousemye-
loma P3-X63-Ag8 cells (Figure 1C). The difference in the
binding of JAA-F11 to 4T1 vs myeloma was statistically
significant in all mAb dilutions (P < .05). The addition of TF-
Ag–BSA to JAA-F11 before incubation with the cell line
caused a 67% inhibition of 4T1 binding and a 65% inhibition
of MDA-MB-435 binding (Figure 1D).
Effects of JAA-F11 on 4T1 Tumor Cells In Vitro
To determine the effects of JAA-F11 mAb on the in vitro
growth of 4T1 cells, with and without JAA-F11 and with con-
trol antibody, quantitation by MTT assays was performed
[38,39]. After performing the assay on five separate days in
sets of eight on each day, the average OD was obtained for
all five experiments. The average of the cells grown with
JAA-F11 was statistically compared to cells grown without
JAA-F11 and to cells grown with IgG3 control antibody. A
statistically significant (P < .005) dose-dependent decrease
in cell growth due to JAA-F11 at 4, 2, and 1 mg/ml was ob-
served in TF-Ag–expressing 4T1 cells, compared to 4T1
cells treated with control IgG3 antibody and without antibody
(average of five experiments; Figure 2A). Similarly, JAA-F11
significantly inhibited the growth of MDA-MB-435 human
breast tumor cells in vitro in a dose-dependent manner
(Figure 2B). Of note, other TF-Ag–targeted antibodies and
lectins were reported to stimulate tumor cell growth; there-
fore, it is important that JAA-F11 did not stimulate tumor cell
growth. This supports the hypothesis that JAA-F11 is able to
bind tumor cells, to block adhesion, and to negatively affect
cell growth in vitro.
Because the binding of some galectins and other lectins
can cause apoptosis [43,44], an assay was performed to
determine if this was the cause of the inhibition of in vitro
growth by JAA-F11. With apoptosis assay, the level of apop-
tosis in positive control cells included in the kit was 29%
compared to 0.3% in negative controls. In 4T1 cells, the per-
centage of apoptotic cells after treatment with JAA-F11 was
2.66 ± 0.34% compared to 3.26 ± 0.27% in untreated con-
trols. Similarly, myeloma cells, although possessing a slightly
higher background level of apoptosis (5.86 ± 1.48%), did not
show an increase in apoptosis level after treatment with
JAA-F11 (8.69 ± 0.76%). Therefore, this assay showed that
no apoptosis resulted from the incubation of mouse breast
cancer cells or control cells with JAA-F11, suggesting that
growth inhibition may be due to antiadhesion or cytostatic
effects rather than due to a cytotoxic mechanism.
The ability of JAA-F11 to induce 4T1 cell killing through a
CDC mechanism was assessed using the CytoTox 96 Non-
radioactive Cytotoxicity Assay based on LDH release. A
mouse anti-mouse H-2Dd mAb was used as positive control,
and baby rabbit serum was used as the source of the
complement. The results of these experiments (Figure 2C)
indicated that, compared to anti–H-2Dd, JAA-F11 antibody
lacks the ability to cause complement-mediated anti– tumor
cytotoxicity in vitro.
Figure 2. (A and B) The effect of JAA-F11 antibody on tumor cell growth in vitro, as measured by MTT assays. (A) TF-Ag+ 4T1 mouse adenocarcinoma cells show
a modest but statistically significant (*) inhibition of growth in response to JAA-F11 antibody compared to no-antibody controls (P < .001) and control IgG3 antibody
(P < .005). The average of five experiments is graphically shown. Error bars represent ± 1 SEM. (B) Dose-dependent inhibition of TF-Ag+ MDA-MB-435 human
breast carcinoma cells in response to JAA-F11 treatment. Data are presented as mean ± 1 SEM. *Statistically significant difference (P < .05) compared to controls.
(C) CDC: compared to anti –H-2Dd antibody, JAA-F11 lacks the ability to cause complement-mediated tumor cell cytotoxicity in vitro.
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Human Models of Metastasis
TF-Ag plays an important role in the primary steps of
breast and prostate cancer metastases by mediating adhe-
sive interactions between metastatic cells and the endo-
thelium [5,17,45,46]. Here, we show that blocking TF-Ag
with JAA-F11 antibody inhibits the stable adhesion of human
breast carcinoma cells to the endothelium in two static ad-
hesion models. In vitro, cancer cell binding to HUVEC mono-
layers (Figure 3A) and HBMEC-60 (Figure 3B) was inhibited
by 54% (P < .05) and 78% (P < .05), respectively. In the
ex vivo–perfused porcine dura mater model, JAA-F11 in-
hibited human breast tumor cell adhesive interactions with
well-differentiatedmicrovessels by 86% (P < .01) (Figure 3C).
Finally, in vivo, JAA-F11 almost completely blocked the
formation of MDA-MB-435 human breast carcinoma cells’
metastatic deposits in mouse lungs after intravenous in-
oculation (Figure 3D–F ).
In Vivo Immunotherapy
In the first series of in vivo immunotherapy experiments
using passive transfer of JAA-F11 antibody, we studied the
effect of JAA-F11 on the growth of primary 4T1 tumors
induced in mouse mammary fat pads. Due to a potential
decrease in active antibody concentration over time, the
dose of JAA-F11 was increased in these experiments to
120 mg/injection compared to the 50-mg/ml dose in MDA-
MB-435 in vivo experiments. The results of these experi-
ments (Figure 4A) show that JAA-F11 did not significantly
affect the growth kinetics of primary 4T1 tumors in vivo.
Thus, the in vitro inhibitory effects of JAA-F11 on 4T1 cell
growth did not translate into a significant inhibition of 4T1
primary tumors in vivo.
In the second series of in vivo immunotherapy experi-
ments, we investigated JAA-F11 effects on 4T1 spontaneous
metastasis and animal survival. Kaplan-Meier analysis
(Figure 4B) demonstrated that immunotherapy with JAA-
F11 antibody provided experimental animals bearing
TF-Ag–expressing 4T1 tumors with a significant survival
advantage. The median survival time of animals in the
PBS-treated group and in the JAA-F11–treated group was
57 and 72 days, respectively, and the difference was statis-
tically significant (P = .05). Furthermore, JAA-F11 immuno-
therapy resulted in a significant reduction in metastatic tumor
burden, reflected by both a dramatic decline in the overall
incidence of spontaneous lung metastasis (from 88% in
the control group to 47% in the JAA-F11–treated group)
and a reduced number of macroscopic metastatic lesions
(Figure 4C and D). Chi-square test for trend analysis dem-
onstrated that the difference in the frequencies of lung
metastasis between the PBS-treated group and the JAA-
F11–treated group was significant (P = .0155). Interestingly,
although the number of lung metastases was lower in the
JAA-F11–treated group, there was no noticeable difference
in the size of metastatic lesions between the groups. Further-
more, only 2 of 10 animals without macroscopic lung metas-
tasis had microscopic metastatic foci, and the rest were
metastasis-free. This suggests that JAA-F11 likely affects
the process of metastatic establishment through antiadhe-
sive mechanisms rather than through the growth of meta-
static lesions. In our experiments, there was no detectable
brain or liver metastasis in animals from either group. Single-
bone (sternum) metastatic lesions were found in 3 of 16
(18.8%) animals in the control group, and in 2 of 20 (10%)
in the JAA-F11–treated group, suggesting that JAA-F11 may
Figure 3. Inhibitory effect of JAA-F11 antibody on breast cancer cell adhesion to the endothelium. The results of static adhesion experiments (A and B) show the
inhibitory effect of JAA-F11 on theMDA-MB-435metastatic human breast carcinoma cell line’s stable adhesion to HUVECmonolayers (A) andHBMEC-60 (B) in vitro.
(C) The effect of JAA-F11 on MDA-MB-435 rolling in well-differentiated microvessels of perfused porcine dura mater ex vivo. (D–F) Inhibition of the formation of
MDA-MB-435 human breast carcinoma subpleural metastatic deposits in the mouse lung 3 hours after intravenous inoculation in vivo by JAA-F11 antibody (E)
compared to untreated controls (D) and control antibodies (F) viewed by fluorescence videomicroscopy. (A–C) *P < .05 and **P < .01. Error bars represent ± 1 SD.
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have an effect on 4T1 metastatic spread to the bone as well.
However, additional experimentation is necessary to support
this hypothesis.
Discussion
The IgG3 JAA-F11 mAb recognizes the TF-Ag that is ex-
pressed on tumor cell surfaces with high specificity. Here, we
demonstrated that JAA-F11 has a modest but statistically
significant inhibitory effect on in vitro 4T1 tumor cell growth
and MDA-MB-435 (Figure 2A and B), as reflected by MTT
assay. This effect was not due to the induction of apoptosis
or CDC. A decrease in MTT reduction to formazan after
treatment with JAA-F11 antibody reflects changes in
mitochondrial function. In the absence of apoptotic response
to JAA-F11 treatment, it may suggest that the antibody could
have a cytostatic effect on cancer cells in vitro, which may
account, in part, for the failure of CDC in vitro. JAA-F11,
however, did not affect the in vivo growth rate of primary 4T1
tumors. We speculate that this could be due to the following
factors: 1) biologically, the growth of 4T1 cells as amonolayer
culture in vitro differs dramatically from in vivo tumor growth
in a mammary fat pad; 2) due to a dilution factor and
administration regimens (twice per week), the effective con-
centrations of the antibody acting on tumor cells in vivo
could have been much lower than those in vitro. Neverthe-
less, even though an in vitro growth-inhibitory effect of JAA-
F11 did not translate into the in vivo inhibition of primary 4T1
tumor growth (Figure 4A), this represents an obvious advan-
tage of JAA-F11 over some other antibodies against TF-Ag,
which enhances in vitro tumor growth [12,30–32]. Glinsky
et al. [46] suggest that the binding of TF-Ag on tumor cells to
galectins on other tumor cells is important in homotypic
cancer cell aggregation, which in turn is important in clono-
genic survival and growth; this mechanism is likely involved
in in vitro proliferation assays and in vivo experiments.
In the series of in vitro, ex vivo, and in vivo experiments,
JAA-F11 dramatically inhibited the adhesion of human breast
carcinoma cells to monolayers of human microvascular en-
dothelial cells, well-differentiated porcine microvessels, and
mouse lung microvasculature (Figure 3). These in vitro and
ex vivo JAA-F11 antimetastatic effects translated into: 1) a
significant (P = .05) extension of the survival time of animals
bearing metastatic 4T1 breast cancer tumors from 57 days
in the PBS-treated control group to 72 days in the JAA-F11–
treated group; 2) considerable reduction in metastatic tumor
burden; and 3) > 50% inhibition of the incidence of spon-
taneous lung metastasis (P = .0155) (Figure 4A–D). These
results support the theory that JAA-F11 has effective anti-
adhesion properties that could be clinically significant in
blocking important steps in the metastasis of tumor cells.
We believe that JAA-F11 antibody disrupts TF-Ag inter-
actionswith its binding partner galectin-3 [5,45,46] or possibly
other galectins. TF-Ag–galectin-3 interactions are involved in
metastatic cell adhesion to the microvascular endothelium,
as well as in the homotypic aggregation of cancer cells with
each other. Most likely, these carbohydrate– lectin inter-
actions, which are rather weak and transient in nature,
Figure 4. (A) JAA-F11 causes no effect on the growth of primary 4T1 tumors in vivo. Error bars represent ±1 SEM. (B) Kaplan-Meier analysis of in vivo
spontaneous metastasis immunotherapy experiments shows that JAA-F11– treated animals (red line) have a significant (*P = .05) survival advantage compared to
control (blue line) mice. (C) Distribution of lung metastasis in control (blue bars) and JAA-F11– treated (red bars) animals. Chi-square analysis shows that JAA-F11
treatment significantly (P = .0155) reduces the amount of spontaneous lung metastasis in the 4T1 model. (D) Representative lungs from control and JAA-F11–
treated mice. Note a decrease in the number of visible metastatic foci on the lungs of JAA-F11– treated mice compared to controls.
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represent someof the earliest events in amultistep cell-to-cell
adhesion process [45,46]. We see a role for TF-Ag–galectin-
3–mediated adhesion in initiating tumor cell binding to
endothelial cells and in mediating subsequent steps in the
metastatic cascade, including invasion and extravasation,
which further determine the fate of metastatic deposits and
the organ specificity of hematogenous cancer metastasis. It
appears that therapeutic inhibition of these early metastasis-
associated adhesive events may have a significant effect on
the outcome of the entire metastatic process and may repre-
sent a new paradigm for therapeutic interventions aiming at
preventing and controlling metastatic cancer spread.
In addition, the data indicate that the passive transfer of
antibody to TF-Ag could be potentially beneficial in patients
with TF-Ag–expressing metastatic breast cancer or other
TF-Ag–expressing cancers. To date, limited clinical success
has been achieved with antibodies or antibody conjugates.
For example, trastuzumab, a mAb targeting Her2/neu, has
received Food and Drug Administration approval for use
in patients with metastatic breast cancer. Similar to JAA-
F11, trastuzumab was developed originally as a mouse mAb.
To reduce patients’ immune reaction to trastuzumab, it was
humanized through a recombinant gene technology so
that only the antigen-binding region retained a mouse origin
whereas the rest of the IgG molecule was made ‘‘human’’
[47]. The same strategy could be used to humanize JAA-
F11 antibody.
Trastuzumab is often used in conjunction with paclitaxel,
which shows a definite synergistic effect in terms of the
number of complete responses and time to disease progres-
sion, such that trastuzumab and paclitaxel, when used to-
gether, produce amuch greater response than the sum of the
responses achieved with either agent used independently
[47]. Thus, it would be of interest to investigate whether JAA-
F11 could synergize cytotoxic drugs. Furthermore, the tras-
tuzumab target Her2/neu is upregulated in about 25% of
breast tumors, whereas JAA-F11 would bind to tumor cells
fromamuch higher percentage of breast cancer patients [47].
Given the chemical specificity of JAA-F11 compared to other
anti–TF-Ag antibodies, yet another potential avenue could
be the use of JAA-F11 as a vehicle for the targeted delivery of
cytotoxic drugs and/or radiopharmaceuticals for therapeutic
and diagnostic purposes. These studies are currently under-
way to determine the broad-spectrum clinical utility of JAA-
F11 mAb.
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